Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Last Update Posted : 2023-05-03
The aim of the trial
- This trial will investigate the brain function of children, adolescents and young adults during and after chemotherapy treatment. It will test cognitive skills such as memory and attention, the brain's electrical activity and involve blood tests for markers related to brain function. People who take part in this trial will be assessed throughout their treatment journey. Understanding how chemotherapy affects the brain in younger people can help to inform research and support. People with osteosarcoma can take part in this trial.
- Country
- Denmark,
- Locations
- Copenhagen,
- Trial Type
- Observational
- Trial Phase
- -
- Trial Status
- Recruiting
- Minimum age
- 7 Years
- Maximum age
- 29 Years
- Key Contact
- Lisa L Hjalgrim, PhD, MD, Barbara Nordhjem,+4535450962, +4535457998,lisa.lyngsie.hjalgrim@regionh.dk, barbara.johanne.thomas.nordhjem@regionh.dk,
- Clinical Trial ID
- NCT05840575
Key Information
- Everyone who takes part in this study will have their brain function assessed. They will be compared with someone of a similar age who does not have cancer.
How the treatment works
- No new treatment is given as part of this trial.
- Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.
Who is the trial for?
- The below points are a summary of who can enter the trial.
- People who have been newly diagnosed with a cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet.
Who is the trial not for?
- The below points are a summary of who can’t enter the trial.
- People who can’t speak and understand Danish
- People with severe intellectual disability or mental health disorders that may affect participation.
- People with cancer that has spread to the brain.
- People who have had a previous chemotherapy or radiotherapy treatment.
Disclaimer
- ONTEX is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team. If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from www.clinicaltrials.gov. The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and summarised the inclusion and exclusion criteria in the ‘who is this trial (not) for’ sections. To the best of our knowledge the clinical trial database is up-to-date and accurate.However, we cannot assume any liability for the accuracy or completeness of the information.